21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
20:13 , Feb 9, 2018 |  BC Week In Review  |  Financial News

mRNA company Moderna raises $500M series G

Moderna Therapeutics Inc. (Cambridge, Mass.) raised $500 million in an untranched series G round on Feb. 1. New investors included an Abu Dhabi Investment Authority subsidiary, BB Biotech AG (SIX:BION; Xetra:BBZA), Julius Baer, EDBI and...
22:07 , Feb 2, 2018 |  BioCentury  |  Finance

Private ambition

BB Biotech AG (SIX:BION; Xetra:BBZA) made a rare private investment in Moderna Therapeutics Inc.’s $500 million series G round and wants to see clinical proof-of-concept data from at least one rare liver disease asset before...
21:29 , Feb 1, 2018 |  BC Extra  |  Financial News

mRNA play Moderna raises $500M series G

Moderna Therapeutics Inc. (Cambridge, Mass.) raised $500 million in an untranched series G round. New investors included an Abu Dhabi Investment Authority subsidiary, BB Biotech AG (SIX:BION; Xetra:BBZA), Julius Baer, EDBI and Sequoia Capital China....
04:28 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Atlas Genetics completes venture financing

Molecular diagnostics company Atlas Genetics Ltd. (Trowbridge, U.K.) raised $35 million in a series D round on Jan. 23. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc, the Johnson...
00:37 , Jan 24, 2017 |  BC Extra  |  Financial News

Atlas Genetics raises $35M in series D

Molecular diagnostics company Atlas Genetics Ltd. (Trowbridge, U.K.) raised $35 million in a series D round. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc (LSE:CSRT), the Johnson & Johnson...
07:00 , Oct 27, 2016 |  BC Extra  |  Financial News

Myovant raises $217.5M in IPO

Endocrine disorder company Myovant Sciences Ltd. (NYSE:MYOV) lost $1.74 (12%) to $13.26 in its first day of trading Thursday after raising $217.5 million through the sale of 14.5 million shares at $15 in an IPO...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Why Tesaro went NOVA

BC Staff  Even though one marketed PARP inhibitor already has demonstrated that its mechanism works as maintenance therapy in platinum-sensitive ovarian cancer, Tesaro Inc. (NASDAQ:TSRO) soared on its positive Phase III data for niraparib (...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Esperion's LDL-C hangover

BC Staff  The fall of Esperion Therapeutics Inc. (NASDAQ:ESPR) continued last month as FDA's refusal to commit to LDL-C lowering as an approvable surrogate endpoint for the company's statin alternative has seen the biotech lose...
07:00 , May 9, 2016 |  BioCentury  |  Finance

Buying the battered

BB Biotech AG (SIX:BION; Xetra:BBZA) is starting to take advantage of a gap between U.S. and European biotech stock declines it believes has grown too wide. The firm is looking to remedy the hosing it...